Loading
HS-20117 is an experimental bispecific antibody from Hansoh BioMedical R&D in phase 3 trials for non-small-cell lung cancer, aimed at EGFR and MET.
HS-20117 (PM1080) is a bispecific antibody developed by Hansoh BioMedical R&D. Its targets are EGFR and MET (the sponsor names EGFR x MET). The sponsor states: A fully-human EGFR-MET IgG1-like bispecific antibody. ClinicalTrials.gov describes the intervention as: Participants will receive HS-20117 once during cycle 1 and once every 2 weeks during subsequent cycles (The duration of each treatment cycle is 28 days). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06417008 (A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer), in non-small-cell lung cancer. The largest, NCT06417008, plans to enrol 1080 participants with primary completion was scheduled for 2026-06-01 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
1.One arm of HS-20117 binds EGFR on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"HS-20117" OR ABSTRACT:"HS-20117" OR TITLE:"PM1080" OR ABSTRACT:"PM1080") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HS-20117, not a curated reading list.
Shares MET, EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares Hansoh Pharmaceutical, Non-small-cell lung cancer and the tag pipeline.
Shares MET, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares Hansoh Pharmaceutical and the tag pipeline.
Shares Hansoh Pharmaceutical, Non-small-cell lung cancer and the tag pipeline.